Eloxx Pharmaceuticals Inc. (ELOX)
ELOX trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1035354/000119312526108687/0001193125-26-108687-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | ELOX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001035354 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $0 |
| Net income | -$6.0M |
| Operating income | -$6.4M |
| Net margin | Needs revenue and net income |
| Operating margin | Operating income not reported |
| Revenue growth | -100.0% |
| Cash | $4.8M |
| Total assets | $5.3M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | Needs market cap and revenue |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-08-11 |
| Cash and burn | $62.0M cash; operating cash flow -$2.7M a quarter. | Report 2026-06-30 |
| Shares outstanding | 4,036,459 (2026-08-07); 2,752,774 three years earlier. | Cover page 2026-08-07 |
| Reverse splits, 3 years | 1; latest on 2026-06-01 | Source 2026-06-01 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Baker Tilly US, LLP, Tewksbury, Massachusetts, United States | PCAOB Form AP 2026-07-06 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q4 2026 2026-06-30 | Not filed | -$4.5M | -$4.8M | $62.0M | $0 | Needs four quarters | 10-Q 2026-08-11 |
| Q3 2026 2026-03-31 | Not filed | -$3.8M | -$5.5M | $6.4M | $0 | Needs four quarters | 10-Q 2026-08-11 |
| Q4 2025 2025-06-30 | Not filed | -$1.9M | -$1.8M | $572K | No debt tags | Needs four quarters | 10-Q 2026-08-11 |
| Q3 2025 2025-03-31 | Not filed | -$1.7M | $1.2M | $450K | No debt tags | Needs four quarters | 10-Q 2026-08-11 |
| Q2 2024 2023-12-31 | Not filed | -$2.9M | -$2.0M | $1.1M | $3.8M | $0 | 10-K 2026-03-17 |
| Q1 2024 2023-09-30 | Not filed | -$3.6M | -$3.5M | $4.8M | $4.6M | Needs four quarters | 10-Q 2023-11-13 |
| Q4 2023 2023-06-30 | Not filed | -$4.3M | -$2.1M | $4.3M | $4.8M | Needs four quarters | 10-Q 2023-11-13 |
| Q3 2023 2023-03-31 | Not filed | -$6.2M | -$6.8M | $4.9M | $4.7M | Needs four quarters | 10-Q 2023-11-13 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2026-11-16 |
| Latest annual report | 10-K | 2026-03-17 |
| Latest quarterly / interim | 10-Q | 2026-11-16 |
| Latest current report | 8-K | 2026-11-16 |
| Latest proxy FORM DEFA14A | DEFA14A | 2023-04-28 |
Source: SEC EDGAR submissions feed, 1,004 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +5.7% |
| 1 month | +3.5% |
| 3 months | -31.0% |
| Year to date | Not enough price history |
| 1 year | Not enough price history |
| From 52-week high | -37.3% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| GRML | Greenland Mines Ltd. | $3.50 | -3.05% | $51.9M |
| INKT | MiNK Therapeutics Inc. | $9.35 | +0.11% | $48.0M |
| PMCB | PharmaCyte Biotech Inc. | $5.57 | -16.62% | $59.8M |
| CGTX | Cognition Therapeutics Inc. | $0.6388 | -6.03% | $60.8M |
| OKYO | OKYO Pharma Limited | $1.18 | -12.96% | $61.7M |
| CSBR | Champions Oncology Inc. | $4.68 | -0.53% | $65.1M |
| ATRA | Atara Biotherapeutics Inc. | $6.40 | -16.88% | $65.2M |
| CRDF | Cardiff Oncology Inc. | $0.8477 | +16.75% | $65.9M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier